Jazz Pharmaceuticals (JAZZ) is back in focus after updated Phase 3 HERIZON GEA 01 data showed Ziihera based regimens cut mortality risk compared with trastuzumab chemotherapy and achieved the longest reported median overall survival in this treatment setting.
Recent trading shows that Jazz Pharmaceuticals’ share price has pulled back, with a 30-day share price return of 13.10% and a 90-day share price return of 19.22% in the red. However, the year to date share price return is 19.42% and the 1-year total shareholder return is 49.70%, suggesting long term holders have still seen strong gains as investors weigh the new Ziihera data alongside expectations for the upcoming earnings report.
Scan beyond Jazz Pharmaceuticals and see how other oncology-focused businesses are priced for potential inflection points with our handpicked 21 high quality undiscovered gems
Jazz Pharmaceuticals now trades well below both analyst targets and one intrinsic value estimate after that sharp pullback. Is the discount simply mispricing the Ziihera story, or is it a fair reflection of the risks buyers still face?
Most Popular Narrative: 30% Undervalued
On the narrative view, Jazz Pharmaceuticals screens as undervalued, with an implied fair value of $294.27 against a last close of $206.78. This puts the recent pullback in a very different light for anyone focused on long term cash generation.
The view on Jazz Pharmaceuticals has shifted toward a more oncology-centric and cash-flow-durability story. The refreshed thesis has moved from a broad, pipeline-driven narrative to a clearer focus on Ziihera-led growth, the resilience of the sleep and epilepsy franchise, and the company’s capital allocation choices.
Previously, oncology growth was spread across several pipeline assets such as dordaviprone and Zepzelca. Now the focus centers on Ziihera as the main oncology driver, with expectations tied to broader HER2 tumor coverage and higher peak sales.
See why 36 investors see Jazz Pharmaceuticals as 30% undervalued.
Result: Fair Value of $294.27 (UNDERVALUED)
Still, the Jazz Pharmaceuticals narrative can be knocked off course if oncology competitors pressure Zepzelca or if patent and generic headwinds bite harder into the sleep franchise.
Find out about the key risks to this Jazz Pharmaceuticals narrative.
Next Steps
Still feeling torn about the Jazz Pharmaceuticals setup after the recent pullback and the mixed oncology and sleep asset story? Dig into the details quickly and weigh the 1 or more risks against the 1 or more rewards for yourself with the 5 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Jazz Pharmaceuticals?
If the Jazz Pharmaceuticals setup has your attention, do not stop here. Use these filters to surface other opportunities before the herd catches on.
- Target resilient balance sheets and steady fundamentals early with a focused list of solid balance sheet and fundamentals (24 results) that keeps weaker businesses off your shortlist.
- Hunt for mispriced quality by scanning a curated 29 high quality undervalued stocks that flags companies where fundamentals and price appear out of sync.
- Zero in on overlooked potential by running a 21 high quality undiscovered gems that highlights under-the-radar stocks with stronger numbers than their profiles suggest.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com